Cellular phase chronic idiopathic myelofibrosis
MONDO:0004463Primary myelofibrosis characterized by bone marrow hypercellularity and the presence of atypical megakaryocytes. There is no increase in the percentage of myeloblasts and no significant increase in reticulin or collagen fibrosis in the bone marrow.
Also known as: Prefibrotic/Early Primary myelofibrosis, chronic idiopathic myelofibrosis, Prefibrotic stage, chronic idiopathic myelofibrosis, cellular phase, primary myelofibrosis, Prefibrotic stage, primary myelofibrosis, Prefibrotic/early stage, PMFPES
3086 clinical trials for this condition and its sub-types, 16 tagged with Cellular phase chronic idiopathic myelofibrosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a modified interferon rein in early myelofibrosis?
Disease control OngoingThis phase 3 trial is testing whether ropeginterferon alfa-2b, a biologic drug, can help control blood cell counts and symptoms in adults with early or low-risk primary myelofibrosis, a bone marrow disorder. Participants receive either the drug or a placebo every two weeks for up…
Phase 3 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis early-phase trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—in adults newly diagnosed with a challenging form of acute myeloid leukemia (AML). The goal is to find the best dose and see if the combo can improve remission rates. About 40 part…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Blood cancer patients' immune system may hold clues to severe COVID-19
Knowledge-focused OngoingThis study examines whether people with certain blood cancers (myeloproliferative neoplasms) have autoantibodies that block a key immune protein called type I interferon. These autoantibodies may increase the risk of severe COVID-19. Researchers will test blood samples from 219 p…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC